Calendario›REGN›Non-interventional

Non-interventional

A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells

Ensayo de REGENERON PHARMACEUTICALS, INC. en Long Term Safety Following GM T Cell Therapy (del registro, en inglés).

Fase

no aplica

Estado

Reclutando pacientes

Participantes

50

previstos

Centros

1

Fin del objetivo primario

jun 2040

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en nov 2025.

Qué mide

Incidence of delayed adverse events considered at least possibly related to prior gene modified T cell therapy (del registro, en inglés) (hasta 15 años)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a prospective study for the Long-Term Follow-Up (LTFU) of safety and efficacy of all participants exposed to gene modified (GM) T cell therapy in accordance with Health Authorities' guidance for participants treated with gene therapy products. Participants who received at least one infusion of gene modified T cells in a 2seventy bio (prior to April 2024) or Regeneron Pharmaceuticals sponsored study will be asked to participate in this LTFU protocol, upon either premature discontinuation from, or completion of the parent treatment protocol. Participants enrolled in this LTFU protocol will have safety assessments, laboratory evaluations, and complete patient-reported outcome (PRO) questionnaires at scheduled intervals as applicable.

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06798298), actualizada en jul 2026.